Q4 EPS Estimate for Jazz Pharmaceuticals Reduced by Analyst

Key Points

• Zacks Research lowered Jazz Pharmaceuticals’ Q4 2026 EPS estimate slightly to $5.28 from $5.29; full-year EPS consensus stands at $21.61.
• Jazz’s latest quarterly results missed EPS expectations, reporting $5.71 versus $6.18, but revenue reached $1.21 billion and rose 15.5% year over year.
• Analyst sentiment remains positive, with a consensus “Buy” rating and an average price target of $289.37, while institutional investors own 89.14% of the stock.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) - Investment analysts at Zacks Research cut their Q4 2026 earnings estimates for Jazz Pharmaceuticals in a research report issued on Thursday, September 24th. Zacks Research analyst Team now expects that the specialty pharmaceutical company will post earnings per share of $5.28 for the quarter, down from their previous forecast of $5.29. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $21.61 per share.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same quarter last year, the company earned ($8.25) EPS. The firm's revenue for the quarter was up 15.5% on a year-over-year basis.

Several other research firms also recently weighed in on JAZZ. The Goldman Sachs Group started coverage on Jazz Pharmaceuticals in a research report on Thursday. They issued a "buy" rating and a $337.00 target price on the stock. Stifel Nicolaus set a $275.00 price target on Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $264.00 to $281.00 and gave the company a "buy" rating in a research note on Wednesday, August 26th. Robert W. Baird increased their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an "outperform" rating in a research note on Tuesday, August 4th. Finally, UBS Group raised their price objective on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a "buy" rating in a report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $289.37.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $237.95 on Monday. Jazz Pharmaceuticals has a 12 month low of $125.79 and a 12 month high of $266.38. The stock has a 50 day moving average of $248.79 and a two-hundred day moving average of $227.88. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The firm has a market cap of $15.45 billion, a P/E ratio of 16.41, a price-to-earnings-growth ratio of 0.21 and a beta of 0.36.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in JAZZ. Sequoia Financial Advisors LLC grew its position in Jazz Pharmaceuticals by 9.4% in the second quarter. Sequoia Financial Advisors LLC now owns 4,527 shares of the specialty pharmaceutical company's stock worth $1,091,000 after acquiring an additional 389 shares during the period. Tidal Investments LLC grew its holdings in shares of Jazz Pharmaceuticals by 8.3% during the 2nd quarter. Tidal Investments LLC now owns 21,028 shares of the specialty pharmaceutical company's stock worth $5,067,000 after purchasing an additional 1,615 shares during the period. WINTON GROUP Ltd acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $386,000. Integrated Wealth Concepts LLC increased its position in shares of Jazz Pharmaceuticals by 27.2% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 1,762 shares of the specialty pharmaceutical company's stock worth $425,000 after purchasing an additional 377 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in Jazz Pharmaceuticals by 15.7% in the 2nd quarter. NewEdge Advisors LLC now owns 2,285 shares of the specialty pharmaceutical company's stock valued at $551,000 after buying an additional 310 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total value of $1,500,780.00. Following the completion of the sale, the director owned 351,875 shares of the company's stock, valued at approximately $88,014,493.75. This represents a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,121 shares of company stock valued at $24,443,842 over the last 90 days. Insiders own 4.10% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc NASDAQ: JAZZ is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz's products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.